Etomidate: Difference between revisions
Ostermayer (talk | contribs) (Text replacement - "Category:Drugs" to "Category:Pharmacology") |
Neil.m.young (talk | contribs) (Text replacement - "==Sources==" to "==References==") |
||
| Line 53: | Line 53: | ||
==See Also== | ==See Also== | ||
== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Revision as of 18:06, 26 June 2016
See critical care quick reference for drug doses by weight.
General
- Type:
- Dosage Forms:
- Common Trade Names:
Adult Dosing
RSI
- 0.3 mg/kg bolus IV
- Standard dose = 20mg
Procedural Sedation
- 0.15 mg/kg bolus IV
- Standard dose = 10mg)
Pediatric Dosing
See critical care quick reference for drug doses by weight.
RSI
- 0.3 mg/kg bolus IV
- Max: 20mg
Procedural Sedation
- (0.15 mg/kg bolus IV
- Max: 10mg
Special Populations
- Pregnancy Rating:
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
- Myoclonus
- Nausea/Vomiting
- Pain at injection site
Controversy
"The available evidence suggests that etomidate suppresses adrenal function transiently without demonstrating a significant effect on mortality. However, no studies to date have been powered to detect a difference in hospital, ventilator, or ICU length of stay or in mortality."[1]
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action: GABA agonist
See Also
References
- ↑ *Hohl CM, Kelly-Smith CH,Yeung TC, Sweet DD, Doyle-Waters MM, Schulzer M. The effect of a bolus dose of Etomidate on cortisol levels, mortality, and health services utilization: a systematic review. Ann Emerg Med. 2010;56(2):105-113.